9989 — Shenzhen Hepalink Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapSuper Stock

Market Cap
HK$6.54bn
Enterprise Value
HK$7.12bn
Revenue
CNY5.28bn

Annual income statement for Shenzhen Hepalink Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,332	6,365	7,159	5,446	5,281
Cost of Revenue
Gross Profit	2,032	1,998	2,296	945	1,748
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4,002	6,139	6,331	6,307	4,540
Operating Profit	1,330	226	828	-862	741
Other Net Non Operating Costs
Net Income Before Taxes	1,328	222	830	-928	726
Provision for Income Taxes
Net Income After Taxes	1,022	233	715	-802	625
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,024	241	727	-783	647
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,024	241	727	-783	647
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.698	0.266	0.485	-0.497	0.357
Dividends per Share